| Name | Atipamezole |
| Description | Atipamezole (Antisedan) is a synthetic α2 adrenergic receptor antagonist. It has also been researched in humans as a potential anti-Parkinsonian drug. |
| In vitro | The affinity of atipamezole for α2-adrenoceptors and its α2/α1 selectivity ratio are considerably higher than yohimbine. Atipamezole is not selective for subtypes of α2-adrenoceptors. It has negligible affinity for 5-HT1, 5-HT2 and I2 bindings sites[1]. |
| In vivo | Atipamezole is well-tolerated in rodents and exhibits modest cardiovascular effects (0.01–1 mg/kg, i.v.) in anesthetized, normotensive rats. It is frequently used by veterinarians to reverse sedation or anesthesia in animals. Atipamezole enhances sexual activity in rats and monkeys and increases pain-related responses in animals with sustained nociception by blocking noradrenergic feedback inhibition of pain. At low doses, it improves alertness, selective attention, planning, learning, and recall in experimental animals, although not necessarily affecting short-term working memory[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 39 mg/mL (183.71 mM), Sonication is recommended.
Ethanol : 39 mg/mL (183.71 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (9.42 mM), Sonication is recommended.
H2O : < 1 mg/mL (insoluble or slightly soluble)
|
| Keywords | α2-adrenoceptor | MPV-1248 | MPV1248 | Inhibitor | inhibit | Beta Receptor | Atipamezole | AdrenergicReceptor | Adrenergic Receptor |
| Inhibitors Related | Trifluoperazine dihydrochloride | Mirtazapine | Octopamine hydrochloride | Gemfibrozil | Buflomedil hydrochloride | Dexmedetomidine hydrochloride | Isoprenaline hydrochloride | D-Mannitol | Mianserin hydrochloride | Trazodone hydrochloride | Atenolol | Doxepin hydrochloride |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Bioactive Compound Library | Anti-Neurodegenerative Disease Compound Library | Membrane Protein-targeted Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Cardiovascular Disease Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Drug Library |
United States
